U.S. Government Exercises Contract Options Valued At $18.9 Million For Emergent BioSolutions (EBS)' Vaccinia Immune Globulin Intravenous Program
8/8/2014 9:45:15 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS). VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract options, valued at $18.9 million over three years, provide for work required to maintain FDA licensure of VIGIV and to collect plasma for future manufacturing.
Help employers find you! Check out all the jobs and post your resume.
comments powered by